Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Diagnostic accuracy of b800 and b1500 DWI-MRI of the pelvis to detect residual rectal adenocarcinoma: a multi-reader study.

Bates DDB, Golia Pernicka JS, Fuqua JL 3rd, Paroder V, Petkovska I, Zheng J, Capanu M, Schilsky J, Gollub MJ.

Abdom Radiol (NY). 2019 Nov 5. doi: 10.1007/s00261-019-02283-x. [Epub ahead of print]

PMID:
31690966
2.

PD-1 Blockade in Advanced Adrenocortical Carcinoma.

Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG, Capanu M, Zamarin D, Saltz LB, Ariyan CE, Untch BR, O'Reilly EM, Gopalan A, Berger MF, Olino K, Segal NH, Reidy-Lagunes DL.

J Clin Oncol. 2019 Oct 23:JCO1901586. doi: 10.1200/JCO.19.01586. [Epub ahead of print]

PMID:
31644329
3.

Dual energy computed tomography analysis in cancer patients: What factors affect iodine concentration in contrast enhanced studies?

Corrias G, Sawan P, Mahmood U, Zheng J, Capanu M, Salvatore M, Spinato G, Saba L, Mannelli L.

Eur J Radiol. 2019 Nov;120:108698. doi: 10.1016/j.ejrad.2019.108698. Epub 2019 Oct 3.

PMID:
31600640
4.

Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.

Moy RH, Dos Santos Fernandes G, Jonsson P, Chou JF, Basunia A, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Gabler A, Berger MF, Tang LH, Hechtman JF, Kelsen DP, Schattner M, Ilson DH, Solit DB, Taylor BS, Schultz N, Capanu M, Janjigian YY.

Oncologist. 2019 Sep 30. pii: theoncologist.2019-0492. doi: 10.1634/theoncologist.2019-0492. [Epub ahead of print]

PMID:
31570517
5.

Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer.

Watt GP, Reiner AS, Smith SA, Stram DO, Capanu M, Malone KE, Lynch CF, John EM, Knight JA, Mellemkjær L, Bernstein L, Brooks JD, Woods M, Liang X, Haile RW, Riaz N, Conti DV, Robson M, Duggan D, Boice JD Jr, Shore RE, Tischkowitz M, Orlow I, Thomas DC, Concannon P, Bernstein JL.

JAMA Netw Open. 2019 Sep 4;2(9):e1912259. doi: 10.1001/jamanetworkopen.2019.12259.

6.

Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma.

Spanheimer PM, Ganly I, Chou J, Capanu M, Ghossein RA, Tuttle RM, Wong RJ, Shaha AR, Untch BR.

Ann Surg Oncol. 2019 Dec;26(13):4423-4429. doi: 10.1245/s10434-019-07869-9. Epub 2019 Sep 23.

PMID:
31549322
7.

Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?

Himoto Y, Cybulska P, Shitano F, Sala E, Zheng J, Capanu M, Nougaret S, Nikolovski I, Vargas HA, Wang W, Mueller JJ, Chi DS, Lakhman Y.

Gynecol Oncol. 2019 Nov;155(2):192-200. doi: 10.1016/j.ygyno.2019.08.011. Epub 2019 Sep 12.

PMID:
31521322
8.

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.

Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK.

Cancer. 2019 Dec 15;125(24):4426-4434. doi: 10.1002/cncr.32463. Epub 2019 Aug 27.

PMID:
31454426
9.

Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.

Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, Tuvy Y, Kundra R, Daian F, Ladanyi M, Kelsen DP, Ilson DH, Berger MF, Tang LH, Solit DB, Diaz LA Jr, Schultz N, Janjigian YY, Ku GY.

Clin Cancer Res. 2019 Oct 15;25(20):6160-6169. doi: 10.1158/1078-0432.CCR-18-3603. Epub 2019 Jul 23.

PMID:
31337644
10.

In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.

Khalil DN, Suek N, Campesato LF, Budhu S, Redmond D, Samstein RM, Krishna C, Panageas KS, Capanu M, Houghton S, Hirschhorn D, Zappasodi R, Giese R, Gasmi B, Schneider M, Gupta A, Harding JJ, Moral JA, Balachandran VP, Wolchok JD, Merghoub T.

J Clin Invest. 2019 Jul 22;129(8):3435-3447. doi: 10.1172/JCI128562. eCollection 2019 Jul 22.

11.

Evaluation of diffusion kurtosis and diffusivity from baseline staging MRI as predictive biomarkers for response to neoadjuvant chemoradiation in locally advanced rectal cancer.

Bates DDB, Mazaheri Y, Lobaugh S, Golia Pernicka JS, Paroder V, Shia J, Zheng J, Capanu M, Petkovska I, Gollub MJ.

Abdom Radiol (NY). 2019 Nov;44(11):3701-3708. doi: 10.1007/s00261-019-02073-5.

PMID:
31154482
12.

Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer.

Wibmer AG, Robertson NL, Hricak H, Zheng J, Capanu M, Stone S, Ehdaie B, Brawer MK, Vargas HA.

Abdom Radiol (NY). 2019 Aug;44(8):2864-2873. doi: 10.1007/s00261-019-02023-1.

PMID:
31030245
13.

Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer.

Won E, Basunia A, Chatila WK, Hechtman JF, Chou JF, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Tuvy Y, Berger MF, Tang L, Kelsen DP, Schattner M, Ilson DH, Capanu M, Solit DB, Schultz N, Janjigian YY.

Clin Cancer Res. 2019 Jul 1;25(13):3811-3817. doi: 10.1158/1078-0432.CCR-18-3789. Epub 2019 Apr 5.

PMID:
30952642
14.

The Influence of Background Signal Intensity Changes on Cancer Detection in Prostate MRI.

Hötker AM, Dappa E, Mazaheri Y, Ehdaie B, Zheng J, Capanu M, Hricak H, Akin O.

AJR Am J Roentgenol. 2019 Apr;212(4):823-829. doi: 10.2214/AJR.18.20295. Epub 2019 Feb 4.

PMID:
30714830
15.

Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.

Halpenny D, Raj M, Rimner A, Zheng J, Capanu M, Ginsberg MS.

Eur Radiol. 2019 Jul;29(7):3696-3704. doi: 10.1007/s00330-018-5937-6. Epub 2019 Jan 28.

PMID:
30689034
16.

Pilot study of rapid MR pancreas screening for patients with BRCA mutation.

Corrias G, Raeside MC, Agostini A, Huicochea-Castellanos S, Aramburu-Nunez D, Paudyal R, Shukla-Dave A, Smelianskaia O, Capanu M, Zheng J, Fung M, Kelsen DP, Mangino DA, Robson ME, Goldfrank DJ, Carter J, Allen PJ, Conti B, Monti S, Do RKG, Mannelli L.

Eur Radiol. 2019 Aug;29(8):3976-3985. doi: 10.1007/s00330-018-5975-0. Epub 2019 Jan 28.

PMID:
30689033
17.

Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes.

Wong W, Lowery MA, Berger MF, Kemel Y, Taylor B, Zehir A, Srinivasan P, Bandlamudi C, Chou J, Capanu M, Varghese A, Yu KH, Iacobuzio-Donahue CA, Shia J, Klimstra DS, Jarnagin WR, Stadler ZK, O'Reilly EM.

Cancer. 2019 May 1;125(9):1441-1448. doi: 10.1002/cncr.31951. Epub 2019 Jan 8.

PMID:
30620386
18.

Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.

Lowery MA, Bradley M, Chou JF, Capanu M, Gerst S, Harding JJ, Dika IE, Berger M, Zehir A, Ptashkin R, Wong P, Rasalan-Ho T, Yu KH, Cercek A, Morgono E, Salehi E, Valentino E, Hollywood E, O'Reilly EM, Abou-Alfa GK.

Clin Cancer Res. 2019 Feb 1;25(3):937-945. doi: 10.1158/1078-0432.CCR-18-1927. Epub 2018 Dec 18.

PMID:
30563938
19.

IDEAL-IQ in an oncologic population: meeting the challenge of concomitant liver fat and liver iron.

Eskreis-Winkler S, Corrias G, Monti S, Zheng J, Capanu M, Krebs S, Fung M, Reeder S, Mannelli L.

Cancer Imaging. 2018 Dec 12;18(1):51. doi: 10.1186/s40644-018-0167-3.

20.

Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma.

Yu KH, Ricigliano M, McCarthy B, Chou JF, Capanu M, Cooper B, Bartlett A, Covington C, Lowery MA, O'Reilly EM.

Cancers (Basel). 2018 Nov 24;10(12). pii: E467. doi: 10.3390/cancers10120467.

21.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
22.

CT Colonography in Preoperative Staging of Colon Cancer: Evaluation of FOxTROT Inclusion Criteria for Neoadjuvant Therapy.

Horvat N, Raj A, Liu S, Matkowskyj KA, Knezevic A, Capanu M, Shia J, Pickhardt PJ, Gollub MJ.

AJR Am J Roentgenol. 2019 Jan;212(1):94-102. doi: 10.2214/AJR.18.19928. Epub 2018 Nov 13.

PMID:
30422707
23.

FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.

Mondaca S, Chatila WK, Bates D, Hechtman JF, Cercek A, Segal NH, Stadler ZK, Varghese AM, Kundra R, Capanu M, Shia J, Schultz N, Saltz L, Yaeger R.

Clin Colorectal Cancer. 2019 Mar;18(1):e39-e52. doi: 10.1016/j.clcc.2018.09.005. Epub 2018 Sep 21.

24.

Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists.

Huicochea Castellanos S, Corrias G, Ulaner GA, Dunphy M, Junting Z, Capanu M, Balachandran V, Giancipoli RG, Monti S, Mannelli L.

Abdom Radiol (NY). 2019 Feb;44(2):586-592. doi: 10.1007/s00261-018-1765-z.

PMID:
30251132
25.

MRI liver fat quantification in an oncologic population: the added value of complex chemical shift-encoded MRI.

Corrias G, Krebs S, Eskreis-Winkler S, Ryan D, Zheng J, Capanu M, Saba L, Monti S, Fung M, Reeder S, Mannelli L.

Clin Imaging. 2018 Nov - Dec;52:193-199. doi: 10.1016/j.clinimag.2018.08.002. Epub 2018 Aug 8.

26.

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.

Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DP, Ilson DH, Yu K, Goldberg Z, Epstein AS, Desai A, Chung V, Chou JF, Capanu M, Solit DB, Schultz N, Janjigian YY.

Gastric Cancer. 2019 Mar;22(2):355-362. doi: 10.1007/s10120-018-0861-7. Epub 2018 Aug 7.

PMID:
30088161
27.

Temporal changes in MRI appearance of the prostate after focal ablation.

Hötker AM, Meier A, Mazaheri Y, Zheng J, Capanu M, Chaim J, Sosa R, Coleman J, Hricak H, Akin O.

Abdom Radiol (NY). 2019 Jan;44(1):272-278. doi: 10.1007/s00261-018-1715-9.

PMID:
30069583
28.

Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior.

Sahin IH, Elias H, Chou JF, Capanu M, O'Reilly EM.

BMC Cancer. 2018 Jul 28;18(1):769. doi: 10.1186/s12885-018-4679-9.

29.

CT features of HER2-mutant lung adenocarcinomas.

Sawan P, Plodkowski AJ, Li AE, Li BT, Drilon A, Capanu M, Ginsberg MS.

Clin Imaging. 2018 Sep - Oct;51:279-283. doi: 10.1016/j.clinimag.2018.05.028. Epub 2018 Jun 7. Review.

30.

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK.

Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.

31.

Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.

van Beek EJAH, Hernandez JM, Goldman DA, Davis JL, McLaughlin K, Ripley RT, Kim TS, Tang LH, Hechtman JF, Zheng J, Capanu M, Schultz N, Hyman DM, Ladanyi M, Berger MF, Solit DB, Janjigian YY, Strong VE.

Ann Surg Oncol. 2018 Jul;25(7):2027-2033. doi: 10.1245/s10434-018-6502-x. Epub 2018 May 3.

32.

Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.

Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, Boice JD, Knight JA, Concannon P, Capanu M, Tischkowitz M, Robson M, Liang X, Woods M, Conti DV, Duggan D, Shore R, Stram DO, Thomas DC, Malone KE, Bernstein L; WECARE Study Collaborative Group, Bernstein JL.

J Clin Oncol. 2018 May 20;36(15):1513-1520. doi: 10.1200/JCO.2017.77.3424. Epub 2018 Apr 5.

33.

Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?

Escalon JG, Harrington KA, Plodkowski AJ, Zheng J, Capanu M, Zauderer MG, Rusch VW, Ginsberg MS.

J Comput Assist Tomogr. 2018 Jul/Aug;42(4):601-606. doi: 10.1097/RCT.0000000000000727.

34.

Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease.

Russo AE, Untch BR, Kris MG, Chou JF, Capanu M, Coit DG, Chaft JE, D'Angelica MI, Brennan MF, Strong VE.

Ann Surg. 2019 Aug;270(2):373-377. doi: 10.1097/SLA.0000000000002749.

PMID:
29578911
35.

What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?

Aherne EA, Plodkowski AJ, Montecalvo J, Hayan S, Zheng J, Capanu M, Adusumilli PS, Travis WD, Ginsberg MS.

Lung Cancer. 2018 Apr;118:83-89. doi: 10.1016/j.lungcan.2018.01.013. Epub 2018 Feb 3.

36.

MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.

Horvat N, Veeraraghavan H, Khan M, Blazic I, Zheng J, Capanu M, Sala E, Garcia-Aguilar J, Gollub MJ, Petkovska I.

Radiology. 2018 Jun;287(3):833-843. doi: 10.1148/radiol.2018172300. Epub 2018 Mar 7.

37.

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, Kaufmann E, Ravichandran V, Mukherjee S, Berger MF, Hyman DM, Klimstra DS, Abou-Alfa GK, Tjan C, Covington C, Maynard H, Allen PJ, Askan G, Leach SD, Iacobuzio-Donahue CA, Robson ME, Offit K, Stadler ZK, O'Reilly EM.

J Natl Cancer Inst. 2018 Oct 1;110(10):1067-1074. doi: 10.1093/jnci/djy024.

38.

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA Jr, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM.

Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. doi: 10.1158/1078-0432.CCR-17-3099. Epub 2018 Jan 24.

39.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.

Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.

40.

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.

Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

PMID:
29295881
41.

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.

Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.

PMID:
29223478
42.

Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.

Pak LM, Kemeny NE, Capanu M, Chou JF, Boucher T, Cercek A, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI.

J Surg Oncol. 2018 Mar;117(4):634-643. doi: 10.1002/jso.24898. Epub 2017 Nov 22.

43.

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.

Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins ZJ, Gross BE, Kelsen DP, Zhang L, Strong VE, Schattner M, Gerdes H, Coit DG, Bains M, Stadler ZK, Rusch VW, Jones DR, Molena D, Shia J, Robson ME, Capanu M, Middha S, Zehir A, Hyman DM, Scaltriti M, Ladanyi M, Rosen N, Ilson DH, Berger MF, Tang L, Taylor BS, Solit DB, Schultz N.

Cancer Discov. 2018 Jan;8(1):49-58. doi: 10.1158/2159-8290.CD-17-0787. Epub 2017 Nov 9.

44.

Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.

Varghese AM, Arora A, Capanu M, Camacho N, Won HH, Zehir A, Gao J, Chakravarty D, Schultz N, Klimstra DS, Ladanyi M, Hyman DM, Solit DB, Berger MF, Saltz LB.

Ann Oncol. 2017 Dec 1;28(12):3015-3021. doi: 10.1093/annonc/mdx545.

45.

A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.

Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, Glassman DC, Covington CM, Brenner R, Hollywood E, Barba A, Johnston A, Liu KC, Feng X, Capanu M, Abou-Alfa GK, O'Reilly EM.

Cancer. 2017 Dec 1;123(23):4556-4565. doi: 10.1002/cncr.30897. Epub 2017 Aug 18.

46.

Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.

Horvat N, Nikolovski I, Long N, Gerst S, Zheng J, Pak LM, Simpson A, Zheng J, Capanu M, Jarnagin WR, Mannelli L, Do RKG.

Abdom Radiol (NY). 2018 Jan;43(1):169-178. doi: 10.1007/s00261-017-1261-x.

47.

O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.

Raj N, Klimstra DS, Horvat N, Zhang L, Chou JF, Capanu M, Basturk O, Do RKG, Allen PJ, Reidy-Lagunes D.

Pancreas. 2017 Jul;46(6):758-763. doi: 10.1097/MPA.0000000000000842.

48.

A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases.

Cercek A, Gendel V, Jabbour S, Moore D, Chen C, Nosher J, Capanu M, Chou JF, Boucher T, Kemeny N, Carpizo DR.

Curr Treat Options Oncol. 2017 Jul;18(7):42. doi: 10.1007/s11864-017-0481-1.

PMID:
28608276
49.

Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.

Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny N, Saltz L, Capanu M, Yaeger R.

Clin Cancer Res. 2017 Aug 15;23(16):4753-4760. doi: 10.1158/1078-0432.CCR-17-0400. Epub 2017 Apr 26.

50.

Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.

Halpenny DF, McEvoy S, Li A, Hayan S, Capanu M, Zheng J, Riely G, Ginsberg MS.

Lung Cancer. 2017 Apr;106:33-36. doi: 10.1016/j.lungcan.2017.01.010. Epub 2017 Jan 22.

Supplemental Content

Loading ...
Support Center